Order Article Reprints

Ivashchenko DV, Che MD, Aysin FR, Tuchkova SN, Korsakov IN, Ianavichiute EI, Ivashchenko MA, Shimanov PV, Kondratieva RV, Shubin AV, et al. Genetic Polymorphisms CYP3A4*22, CYP3A5*3, and CYP2D6 Predicted Phenotypes Are Not Associated with Antipsychotic Treatment Outcomes in Neurotypical Prepubertal Boys with Conduct Disorders. Pharmaceuticals. 2026; 19(9):1401. https://doi.org/10.3390/ph19091401

Ivashchenko, Dmitriy V., Mikhail D. Che, Farid R. Aysin, Svetlana N. Tuchkova, Ivan N. Korsakov, Ekaterina I. Ianavichiute, Mariia A. Ivashchenko, Pavel V. Shimanov, Rimma V. Kondratieva, Artem V. Shubin, and et al. 2026. "Genetic Polymorphisms CYP3A4*22, CYP3A5*3, and CYP2D6 Predicted Phenotypes Are Not Associated with Antipsychotic Treatment Outcomes in Neurotypical Prepubertal Boys with Conduct Disorders" Pharmaceuticals 19, no. 9: 1401. https://doi.org/10.3390/ph19091401

Ivashchenko, D. V., Che, M. D., Aysin, F. R., Tuchkova, S. N., Korsakov, I. N., Ianavichiute, E. I., Ivashchenko, M. A., Shimanov, P. V., Kondratieva, R. V., Shubin, A. V., Mirzaev, K. B., Shevchenko, Y. S., & Sychev, D. A. (2026). Genetic Polymorphisms CYP3A4*22, CYP3A5*3, and CYP2D6 Predicted Phenotypes Are Not Associated with Antipsychotic Treatment Outcomes in Neurotypical Prepubertal Boys with Conduct Disorders. Pharmaceuticals, 19(9), 1401. https://doi.org/10.3390/ph19091401